×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MIRM – mirum pharmaceuticals, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MIRM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/5
08:51 am
mirm
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Medium
Report
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
2/5
08:00 am
mirm
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
Medium
Report
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
2/3
07:17 am
mirm
Mirum doubles down on diversified rare disease strategy [Yahoo! Finance]
Low
Report
Mirum doubles down on diversified rare disease strategy [Yahoo! Finance]
1/31
03:29 pm
mirm
Is Mirum Pharmaceuticals on a Strong Path to Profitability? [Yahoo! Finance]
Low
Report
Is Mirum Pharmaceuticals on a Strong Path to Profitability? [Yahoo! Finance]
1/30
12:26 pm
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Morgan Stanley from $95.00 to $123.00. They now have an "overweight" rating on the stock.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Morgan Stanley from $95.00 to $123.00. They now have an "overweight" rating on the stock.
1/27
06:41 am
mirm
Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline [Yahoo! Finance]
Low
Report
Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline [Yahoo! Finance]
1/26
10:46 am
mirm
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease [Yahoo! Finance]
1/26
08:04 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at HC Wainwright from $102.00 to $130.00. They now have a "buy" rating on the stock.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at HC Wainwright from $102.00 to $130.00. They now have a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2025
04:01 pm
mirm
mirum pharmaceuticals, inc. - common stock
BEAT
Report
-1.2%
mirum pharmaceuticals, inc. - common stock
8/6/2025
04:01 pm
mirm
mirum pharmaceuticals, inc. - common stock
BEAT
Report
12.0%
mirum pharmaceuticals, inc. - common stock
5/7/2025
04:01 pm
mirm
mirum pharmaceuticals, inc. - common stock
BEAT
Report
9.8%
mirum pharmaceuticals, inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
12/11
09:04 am
Reiterates
Strong-Buy
Strong-Buy
Raymond James Financial, Inc.
Low
Report
0.4%
Date
Time
Symbol
Headline
Impact
2/3
09:45 pm
mirm
Form 4 Mirum Pharmaceuticals, For: Feb 02 Filed by: Radovich Peter
Low
Report
Form 4 Mirum Pharmaceuticals, For: Feb 02 Filed by: Radovich Peter
2/3
09:45 pm
mirm
Form 4 Mirum Pharmaceuticals, For: Feb 02 Filed by: Peetz Christopher
Low
Report
Form 4 Mirum Pharmaceuticals, For: Feb 02 Filed by: Peetz Christopher
2/3
09:45 pm
mirm
Form 4 Mirum Pharmaceuticals, For: Jan 31 Filed by: Howe Jolanda
Low
Report
Form 4 Mirum Pharmaceuticals, For: Jan 31 Filed by: Howe Jolanda
2/2
08:29 pm
mirm
Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda
Low
Report
Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda
2/2
08:26 pm
mirm
Form 144 Mirum Pharmaceuticals, Filed by: Radovich Peter
Low
Report
Form 144 Mirum Pharmaceuticals, Filed by: Radovich Peter
2/2
08:21 pm
mirm
Form 144 Mirum Pharmaceuticals, Filed by: Peetz Christopher
Low
Report
Form 144 Mirum Pharmaceuticals, Filed by: Peetz Christopher
1/30
06:30 pm
mirm
Form 4 Mirum Pharmaceuticals, For: Jan 28 Filed by: BJERKHOLT ERIC
Low
Report
Form 4 Mirum Pharmaceuticals, For: Jan 28 Filed by: BJERKHOLT ERIC
1/30
06:30 pm
mirm
Form 4 Mirum Pharmaceuticals, For: Jan 28 Filed by: Quan Joanne
Low
Report
Form 4 Mirum Pharmaceuticals, For: Jan 28 Filed by: Quan Joanne
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/13
Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast
111.0%
3/23 Form 4 Mirum Pharmaceuticals, For: Mar 19 Filed by: Tucker Edwin Jonathan 20.8%
3/12 Form 10-K Mirum Pharmaceuticals, For: Dec 31 16.2%
1/16 Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund 15.2%
12/7 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%
4/17 Mirum Pharmaceuticals (NASDAQ: MIRM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/28 Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer 5.5%
4/30 Form 3 Mirum Pharmaceuticals, For: Apr 28 Filed by: Radovich Peter 5.4%
2/18 Mirum Pharmaceuticals to Participate at Four Upcoming Conferences 5.0%
4/9 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 4.7%
3/23 Form 4 Mirum Pharmaceuticals, For: Mar 19 Filed by: Tucker Edwin Jonathan 20.8%
3/12 Form 10-K Mirum Pharmaceuticals, For: Dec 31 16.2%
1/16 Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund 15.2%
12/7 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%
4/17 Mirum Pharmaceuticals (NASDAQ: MIRM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/28 Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer 5.5%
4/30 Form 3 Mirum Pharmaceuticals, For: Apr 28 Filed by: Radovich Peter 5.4%
2/18 Mirum Pharmaceuticals to Participate at Four Upcoming Conferences 5.0%
4/9 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 4.7%
TOP News Decliners
3/17
Mirum Pharmaceuticals (MIRM) Investor Presentation - Slideshow [Seeking Alpha]
-10.7%
1/8 Mirum Pharmaceuticals Announces Pricing of Public Offering -6.6%
1/6 Form S-1 Mirum Pharmaceuticals, -6.0%
12/17 Mirum Pharmaceuticals (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc from $21.00 to $30.00. They now have a "buy" rating on the stock. -5.8%
4/16 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.6%
1/9 Form 424B4 Mirum Pharmaceuticals, -5.0%
8/28 Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update -4.8%
8/12 Mirum Pharmaceuticals (NASDAQ: MIRM) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -4.6%
12/28 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.4%
9/26 Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference -3.9%
1/8 Mirum Pharmaceuticals Announces Pricing of Public Offering -6.6%
1/6 Form S-1 Mirum Pharmaceuticals, -6.0%
12/17 Mirum Pharmaceuticals (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc from $21.00 to $30.00. They now have a "buy" rating on the stock. -5.8%
4/16 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.6%
1/9 Form 424B4 Mirum Pharmaceuticals, -5.0%
8/28 Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update -4.8%
8/12 Mirum Pharmaceuticals (NASDAQ: MIRM) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -4.6%
12/28 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.4%
9/26 Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference -3.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: